Nasopharyngeal Carcinoma (NPC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Nasopharyngeal Carcinoma (NPC) is characterized by early extensive local infiltration, high hematogenous dissemination, early lymphatic spread, and a high mortality rate. According to the research, there were an estimated 129,079 new cases of NPC and 72,987 NPC‑related deaths in 2018 worldwide. In 2018, there were 60,558 new NPC cases (47.7% of total global cases) and 31,413 NPC‑related deaths in China. Considering the complexity of the disease pathophysiology and diagnosis, treatment, and prognosis, the need for individualized treatment. Therefore, researchers are focusing on the identification of molecular biomarkers to establish new non‑invasive early diagnostic methods, ideal treatment regimens, efficacy evaluation standards, and prognostic indicators for NPC.
·
Symptoms of NPC are not conclusive at early
stages, and NPC is not conducive to imaging screening; more than 70% of
patients have locoregionally advanced (LA)‑NPC at the time of initial diagnosis.
Thelansis’s “Nasopharyngeal Carcinoma
(NPC) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Nasopharyngeal
Carcinoma (NPC) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Nasopharyngeal Carcinoma (NPC) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Nasopharyngeal Carcinoma (NPC) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment